VQ Biomedical

Executive Summary

VQ Biomedical is a private, pre-revenue medical device company developing a minimally invasive intravascular oxygenation catheter for patients with respiratory failure. Founded in 2018 and based in San Diego, the company aims to deliver oxygen directly into the bloodstream, independent of the lungs, allowing them to rest and heal. This novel approach has the potential to address a significant unmet need in critical care, where current therapies like mechanical ventilation can cause further lung injury. The company has secured seed funding from venture capital and non-dilutive government grants, validating the technology's promise. As a pre-clinical stage company, VQ Biomedical faces typical early-stage risks including regulatory hurdles and clinical validation, but its differentiated platform could offer a paradigm shift in respiratory support.

Upcoming Catalysts (preview)

• Q3 2026FDA IDE Approval for First-in-Human Study40% success
• Q2 2026Completion of Preclinical Proof-of-Concept Studies70% success
• Q4 2026Series A Financing Round50% success